Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Neely

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Clinical Pharmacokinetics|March 12, 2020
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted ChildrenHanen Marsit, Michaël Philippe, Michael Neely, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|September 19, 2012
Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosisChristoph Schaudinn, Amita Gorur, Paul Webster, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|December 19, 2012
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jawParish P Sedghizadeh, Allan C Jones, Chris LaVallee, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2015
Achieving target voriconazole concentrations more accurately in children and adolescentsMichael Neely, Ashley Margol, Xiaowei Fu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 14, 2013
Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric BayesianTatiana Tatarinova, Michael Neely, Jay Bartroff, et al.
The Pediatric Infectious Disease Journal|September 7, 2013
Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescentsMichael Neely, Richard Rutstein, Gabriela Del Bianco, et al.
Antimicrobial Agents and Chemotherapy|January 20, 2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance SuppressionG L Drusano, Stephanie Rogers, David Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 6, 2015
Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?Pierre-André Billat, Jean-Baptiste Woillard, Marie Essig, et al.
Antimicrobial Agents and Chemotherapy|February 3, 2016
Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized TherapyLuc J Huurneman, Michael Neely, Anette Veringa, et al.
Clinical Pharmacokinetics|March 7, 2020
Development of Population and Bayesian Models for Applied Use in Patients Receiving CefepimeJiajun Liu, Michael Neely, Jeffrey Lipman, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Clinical Pharmacokinetics|March 12, 2020
Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted ChildrenHanen Marsit, Michaël Philippe, Michael Neely, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|September 19, 2012
Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosisChristoph Schaudinn, Amita Gorur, Paul Webster, et al.
Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology|December 19, 2012
Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jawParish P Sedghizadeh, Allan C Jones, Chris LaVallee, et al.
Antimicrobial Agents and Chemotherapy|March 18, 2015
Achieving target voriconazole concentrations more accurately in children and adolescentsMichael Neely, Ashley Margol, Xiaowei Fu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 14, 2013
Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric BayesianTatiana Tatarinova, Michael Neely, Jay Bartroff, et al.
The Pediatric Infectious Disease Journal|September 7, 2013
Use of nucleoside reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescentsMichael Neely, Richard Rutstein, Gabriela Del Bianco, et al.
Antimicrobial Agents and Chemotherapy|January 20, 2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance SuppressionG L Drusano, Stephanie Rogers, David Brown, et al.
The Journal of Antimicrobial Chemotherapy|November 6, 2015
Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?Pierre-André Billat, Jean-Baptiste Woillard, Marie Essig, et al.
Antimicrobial Agents and Chemotherapy|February 3, 2016
Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized TherapyLuc J Huurneman, Michael Neely, Anette Veringa, et al.
Clinical Pharmacokinetics|March 7, 2020
Development of Population and Bayesian Models for Applied Use in Patients Receiving CefepimeJiajun Liu, Michael Neely, Jeffrey Lipman, et al.
Pageof 10